A follow-up of GLACIER (a study to investigate the Genetics of LobulAr Carcinoma In situ in EuRope) and ICICLE (A study to Investigate the genetiCs of In situ Carcinoma of the ductaL subtypE).

Did you take part in the ICICLE or GLACIER study sponsored by QMUL? We are gathering information on those that took part and consented for their data/sample to be used in future studies to see if their cancer has recurred or progressed since the close of these studies, as part of a follow-up study (REC reference: 18/SW/0052). We have sought s251 support from the Health Research Authority (HRA) on advice from the Confidential Advisory Group (CAG) to allow us to request outcome data from NHS England, including data allowing to determine recurrences, and survival data. The s251 support allows us to share the personal details you have provided to us (Name/DOB/Post code or NHS Number) with NHS England to link you to their records, and obtain this outcome data. This follow-up study is to see whether any of the genes or SNPs that predispose to lobular breast cancer and DCIS affect survival or progression, and identify tumour biomarkers associated with survival and progression. King’s College London are now looking after the initial studies and the follow-up study, and will be working on the follow-up study alongside Guy’s & St Thomas’ Hospital. This data is planned to be stored securely for up to 15 years. You can find more details on use of personal details for research in the links below. You are free to withdraw at any time, without giving a reason, and we will fully respect your wishes. If you have any questions or concerns, or if you wish to withdraw from the study, please contact Professor Elinor Sawyer or Jasmine Timbres from the King’s College London Breast Cancer Genetics Team.

• Professor Elinor Sawyer
• Jasmine Timbres
• King's College London personal data in research
• Guy’s & St Thomas’ Hospital Data & Research

Molecular Analysis of the Sloane Project

The Sloane Project is a UK wide prospective audit of screen detected non-invasive and atypical breast hyperplasias. Non invasive breast neoplasia accounts for 25% of all ‘breast cancers’ detected through breast screening and includes ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Atypical hyperplasias are high risk benign lesions and are found in 10% of benign biopsies performed through the screening programme. The importance of these lesions rests on the increased risk of subsequently developing invasive breast cancer with DCIS at highest risk (20 times greater than the general population) followed by LCIS (2-11 times greater) and atypical breast hyperplasia (4 times greater). The Sloane project data are held by Public Health England and provide full and detailed information about the patients' journey from diagnosis to treatment and outcome. The project aims to increase the understanding of these early breast lesions which can lead to breast cancer.

Prevent Ductal Carcinoma in Situ Invasive Overtreatment Now – PRECISION

In order to reduce the overtreatment of pre-cancerous conditions that do not progress to invasive disease, the Breast Cancer Genetics group are looking at cohort of patients who have had Ductal Carcinoma in situ (DCIS) in the past in the hopes of identifying any markers that can help in predicting the recurrence or progression from DCIS to invasive cancer.